Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amgen (GB:0R0T)
LSE:0R0T
Amgen (0R0T) Share Price & Analysis
2 Followers
0R0T Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$206.93 - $326.56
Previous Close$269.5
Volume837.00
Average Volume (3M)39.60K
Market Cap
$144.69B
Enterprise Value$198.36B
Total Cash (Recent Filing)$10.94B
Total Debt (Recent Filing)$64.61B
Price to Earnings (P/E)21.6
Beta0.46
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-Date
May 16, 2024Dividend Yield3.21%
Share Statistics
EPS (TTM)12.48
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume39,596
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.04
Enterprise Value/Gross Profit10.05
Enterprise Value/Ebitda13.40
Forecast
1Y Price Target
$310.41Price Target Upside15.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
Amgen News
PremiumPress Releases
AMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDENDBulls Say, Bears Say
Bulls Say
Drug EfficacyTezspire demonstrates significant reduction in COPD exacerbations, especially among patients with higher eosinophil counts, indicating its potential to outperform competitors.
Market PotentialWith its potential for broader application in the COPD market and a more convenient dosing schedule, Tezspire could capture a significant market share, presenting a multi-billion dollar opportunity.
Product PerformanceSales of Repatha and bone health products are outperforming, potentially balancing revenue shortfalls from other segments.
Bears Say
Competitive Market PositionInvestor confidence in MariTide may be shaken due to the robustness of VK2735's trial results and its implications on market positioning.
Drug Efficacy ConcernsThe overall phase 2 trial for Tezspire missed the primary endpoint, which might raise concerns about its efficacy.
Earnings Forecast1Q earnings for AMGN could miss expectations with predicted ~2% revenue and ~6-7% EPS shortfall.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.08% Insiders
21.40% Mutual Funds
28.76% Other Institutional Investors
48.76% Public Companies and
Individual Investors
0R0T FAQ
What was Amgen’s price range in the past 12 months?
Amgen lowest share price was $206.93 and its highest was $326.56 in the past 12 months.
What is Amgen’s market cap?
Currently, no data Available
When is Amgen’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Amgen’s earnings last quarter?
Currently, no data Available
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Undervalued.
Does Amgen pay dividends?
Amgen pays a Quarterly dividend of $2.25 which represents an annual dividend yield of 3.21%. See more information on Amgen dividends here
What is Amgen’s EPS estimate?
Amgen’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Amgen have?
Amgen has 535,918,900 shares outstanding.
What happened to Amgen’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Amgen?
Among the largest hedge funds holding Amgen’s share is PRIMECAP Management Co. It holds Amgen’s shares valued at 4B.
---
Amgen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$310.41 (15.18% Upside)
$310.41 (15.18% Upside)
Blogger Sentiment
Bullish
GB:0R0T Sentiment 90%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
16.85%
12-Months-Change
Fundamentals
Return on Equity
135.79%
Trailing 12-Months
Asset Growth
49.19%
Trailing 12-Months
Company Description
Amgen
Founded in 1980, California-based Amgen, Inc. is one of the world's leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.
---
0R0T Stock 12 Months Forecast
Average Price Target
$310.41
▲(15.18% Upside)
Technical Analysis
Best Analysts Covering 0R0T
1 Year
1 Year Success Rate
21/27 ratings generated profit
1 Year Average Return
+14.91%
reiterated a buy rating 14 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +14.91% per trade.
---